Drug Discovery Featured Articles & Applications

  1. Defining The RNA Therapeutics Industry In 2023 1/16/2023

    Four executives outline which industry challenges, strategic considerations, and opportunities should be top of mind as RNA therapeutics companies establish their to-do lists for 2023.

  2. AI/ML In Drug Discovery & Development: Potential And Challenges 1/11/2023

    Selecting the wrong target molecule or focusing on the wrong area of investigation can cause major delays and waste valuable time and resources. Artificial intelligence (AI) and machine learning (ML) can help drug discovery researchers minimize these missteps in a few key ways.

  3. FDA Seeks Comment On Delaying, Denying, Limiting, Refusing Inspections 1/9/2023

    The FDA has released for public comment a proposed draft guidance, Circumstances that Constitute Delaying, Denying, Limiting, or Refusing a Drug or Device Inspection Revision 1. The guidance shares examples of reasonable and unreasonable circumstances. Submit public comments by February 14, 2023.

  4. Will ESG Be 2023’s Hottest Business Topic In Bio/Pharma? 1/6/2023

    Sustainability used to be just about saving the planet. Today it has morphed into an umbrella term for environmental, social, and governance (ESG) issues. Mentions of ESG and related topics in pharma companies’ filings more than tripled between 2016 and 2021. What are the commitments that companies are making, and which Big Pharma companies are making those commitments?

  5. The Need — And Opportunity — To Develop Broad-Spectrum Antivirals 1/3/2023

    One factor contributing to the lack of broad-spectrum antivirals is a lag in testing technology for viruses. This article discusses interferons (a group of signaling proteins secreted by cell types to coordinate the body’s natural antiviral responses) and other potential broad-spectrum antivirals, as well as the new testing initiatives being conducted.

  6. Outsourcing Strategies For Maximizing Drug Exclusivity 12/19/2022

    Once a drug target has been identified, bio/pharma companies often take steps to outsource the process of getting this target commercialized and begin to work with a CDMO. The time devoted to R&D tends to erode the patent exclusivity period attached to a drug or biological product. It is extremely important that contractual agreements clearly spell out ownership of discoveries and data uncovered during the outsourced development process.

  7. 6 Tips For Successful Drug Discovery Teamwork 12/16/2022

    While people don’t always think about the choreography of good scientific teamwork, there are factors that should be considered and skills that can be developed to increase a drug discovery team’s overall effectiveness and chance of success.

  8. Leveraging Human Genetics To Advance Cell Therapies For Treatment Of Blood Cancers 12/13/2022

    Leveraging human genetics data early in the drug discovery process to inform target prioritization is a powerful approach to mitigate risk and increase the likelihood of advancing safe therapies that make a transformative impact in patients’ lives.

  9. How To Close The Looming Life Sciences Data Storage Gap 12/9/2022

    Organizations across life sciences are facing a data storage dilemma: how to balance the need to store and potentially monetize mushrooming amounts of data while managing IT budgets and limiting the total cost of ownership.

  10. Rising Interest Rates Skew Risk-Return Paradigm For Life Sciences 12/6/2022

    Rising interest rates, imploding cryptocurrencies, and erratic equities markets have upended assumptions about risk and returns during 2022. The “risk-free” rate has surged to more than 4% as of late November. Your pharma, biotech, or medical device company looking to raise cash needs to take the key considerations shared in this article into account.